Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Financing Activities (2016 - 2025)

Protalix BioTherapeutics has reported Cash from Financing Activities over the past 14 years, most recently at $146000.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $146000.0 for Q4 2025, down 95.97% from a year ago — trailing twelve months through Dec 2025 was $9.3 million (down 33.67% YoY), and the annual figure for FY2025 was $9.3 million, up 155.53%.
  • Cash from Financing Activities for Q4 2025 was $146000.0 at Protalix BioTherapeutics, down from $4.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PLX hit a ceiling of $42.1 million in Q1 2021 and a floor of -$26.0 million in Q3 2021.
  • Median Cash from Financing Activities over the past 5 years was $4.1 million (2022), compared with a mean of $5.0 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 681.17% in 2021 and later surged 200.72% in 2022.
  • Protalix BioTherapeutics' Cash from Financing Activities stood at -$4.0 million in 2021, then surged by 200.72% to $4.1 million in 2022, then skyrocketed by 156.02% to $10.4 million in 2023, then tumbled by 65.24% to $3.6 million in 2024, then crashed by 95.97% to $146000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $146000.0 (Q4 2025), $4.1 million (Q2 2025), and $5.1 million (Q1 2025) per Business Quant data.